VolitionRx Limited (NYSE:VNRX) has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.
Volition’s major achievements in 2022 include:
Expanding access to the Nu.Q® Vet Cancer Test on a worldwide basis
Achieving a CE mark for Nu.Q® NETs
Launching its U.S. clinical product development and regulatory programs
Developing its Nu.Q® pipeline  Â
Scaling up its operations  Â
Read Volition’s Business Review here or watch the video below.
Cameron Reynolds, President and Group Chief Executive Officer, said: “2022 was a phenomenal year for Volition. For over a decade we have sought to advance the science of epigenetics, develop and reï¬ne our technology to be – what we believe to be – the best-in-class in the diagnostics industry.
“Powered by Nu.Q®, our Nucleosomics™ technology has the potential to play an important role in the ï¬ght to save lives and improve outcomes worldwide and we are thrilled that our Nu.Q® Vet Cancer Test is now commercially available, with plans to commercialize Nu.Q® NETs also well underway. We expect that 2023 will be another exciting year.”
